OPGS Overview
- Status
-
Private
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
2
OPGS General Information
Description
Developer of pharmaceutical antidotes for organophosphorus poisoning. The company's technology enables reactivation of acetylcholinesterase and central nervous system targeting, enabling military and civilian personnel to use neuroprotective compounds that neutralize chemical warfare agents and pesticides.
Contact Information
Corporate Office
- Paris
- France
Corporate Office
- Paris
- France
OPGS Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Accelerator/Incubator | 01-Jan-2024 | Completed | Startup | |||
| 1. Accelerator/Incubator | 01-Jan-2019 | Completed | Startup |
OPGS Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
OPGS Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Paris Biotech Sante | Accelerator/Incubator | |||
| Deeptech Founders | Accelerator/Incubator |
OPGS FAQs
-
Where is OPGS headquartered?
OPGS is headquartered in Paris, France.
-
What industry is OPGS in?
OPGS’s primary industry is Drug Discovery.
-
Is OPGS a private or public company?
OPGS is a Private company.
-
What is OPGS’s current revenue?
The current revenue for OPGS is .
-
Who are OPGS’s investors?
Paris Biotech Sante and Deeptech Founders have invested in OPGS.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
